Skip to main content
OpenTrials
Completed

NCT Number: NCT03203499

A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol

This is a single-center, randomized, double-blind, placebo-controlled, single-ascending-dose study to evaluate the safety and tolerability of the coadministration of up to 6 dose levels of ANS-6637 and EtOH in healthy male moderate alcohol drinkers. The study will include a screening visit, a qualification visit, a Treatment Phase and follow-up.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Vince and Associates

Overland Park, Kansas, 66212, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male adults, between 21 and 45 years of age, inclusive.
  • Body mass index (BMI) within 19.0 to 34.0 kg/m2, inclusive (minimum weight of at least 50.0 kg at screening).
  • Resting semisupine vital signs at screening and each clinic admission within the following ranges:
  • Systolic blood pressure 90 to 140 mmHg
  • Diastolic blood pressure of 50 to 90 mmHg
  • Heart rate of 40 to 90 beats per minute (bpm)
  • Current alcohol users who are self-reported moderate drinkers, defined as having consumed 7 to 21 standard drinks per week on average in the 6 months prior to screening and having consumed ≥5 standard drinks on at least 1 occasion in the 30 days prior to screening. One standard alcoholic drink (14 grams of EtOH) is equivalent to 43 mL (1.5 oz) hard liquor, 142 mL (5 oz) wine or 341 mL (12 oz) beer.

Exclusion criteria

  • Drug or alcohol dependence within the 12 months prior to screening (except nicotine), as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).
  • Subjects who have ever been in treatment for substance use disorder(s) (except smoking cessation).
  • Current or prior diagnosis of any condition where alcohol consumption is contraindicated, including, but not limited to, hypertriglyceridemia, pancreatitis, liver disease, porphyria, and/or congestive heart failure, that is clinically relevant, as judged by the investigator or designee.
  • Positive urine drug test for EtOH, cocaine, oxycodone and other opioids, amphetamines, benzodiazepines and/or cannabinoids at clinic admission. Positive results may be repeated and/or subjects rescheduled at the investigator's or designee's discretion.

Treatment and study plan

ANS-6637 Oral Tablet

Drug

Ascending single doses administered orally.

Placebo oral tablet

Drug

Placebo administered orally.

Primary outcomes

  1. Incidence and severity of adverse events

    Time frame: Up to 36 hours postdose

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Up to 48 hours postdose

  2. Time to maximum observed serum concentration (Tmax)

    Time frame: Up to 48 hours postdose

  3. Areas under the plasma concentration-time curve from time zero to last quantifiable concentration (AUClast)

    Time frame: Up to 48 hours postdose

  4. Ethanol Consumption

    Time frame: Up to 6 hours postdose

  5. Modified 5-Item Drug Effects Questionnaire (mDEQ-5)

    Time frame: Up to 6 hours postdose

Sponsors and collaborators

Lead sponsor

Amygdala Neurosciences, Inc.

Industry

Registry information

Official study title

A Phase 1b, Proof of Concept, Dose-Ranging Study to Evaluate the Safety of the Coadministration of Ascending Doses of ANS-6637 and Ethanol in Healthy Male Moderate Drinkers

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jun 29, 2017
Registry last updated
Jan 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.